Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/iBio, Inc./ 10-Q

Quarterly Report · 10-Q

iBio, Inc.

IBIONASDAQEQUITYCurrent

Quarterly Report

Filed Feb 10, 2025Accepted Feb 10, 2025, 4:15 PM ESTCIK 1420720Accession 0001420720-25-000012
View company →Permanent SEC source ↗
Share

Company context

iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

Current securities

IBIONASDAQ · EQUITY · Current

Recent company filings

  1. Regulation FD Disclosure · Other EventsSep 14, 2026
  2. ARS filingSep 4, 2026
  3. DEF 14A filingSep 4, 2026
  4. Results of Operations and Financial ConditionAug 28, 2026
  5. 10-K filingAug 28, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗